BioSpace

JPM26 Day 1: Obesity Front-and-Center, Q4 Sales Beats

Obesity took center stage on the first day of the 2026 J.P. Morgan Healthcare Conference, with industry frontrunners Eli ...

Regeneron stock lagged behind the S&P 500 last year. Why this firm moved off the sidelines.

Regeneron was up 4.7% at $813.38. If the gains hold, the stock will notch its highest close since Nov. 12, 2024, when it ...

REGN Soars 41% in Six Months: Is There More Upside Potential in 2026?

Regeneron shares are up 41% in six months as FDA approvals, strong Dupixent profits and oncology gains lift investor confidence.
Healio

FDA approves Eylea HD for macular edema after retinal vein occlusion

Please provide your email address to receive an email when new articles are posted on . The decision is supported by positive visual acuity gains found in the phase 3 QUASAR trial. This is the fourth ...
Benzinga.com

Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following ...
Barron's

EYLEA HD(R) (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period ...
Seeking Alpha

EYLEA HD® (aflibercept) Injection 8 mg Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications

TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...
contemporarypediatrics

FDA approves EYLEA HD injection 8 mg to treat macular edema following RVO and monthly dosing

The agency approved a monthly dosing option for select patients acorss all approved indications, including wAMD, DME, DR, and RVO. FDA approved aflibercept (Eylea HD) 8 mg for macular edema following ...